Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anbio BiotechnologyNNNN +1.64%24 Return-on-Tangible-Asset is 18.00% as of Dec. 2025, which is 31% below its 10-year median of 26.05. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Anbio Biotechnology ranks better than 97.31% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Anbio Biotechnology's annualizedNet Income for the quarter that ended in Dec. 2025 was $5.21 Mil. Anbio Biotechnology's average total tangible assets for the quarter that ended in Dec. 2025 was $28.96 Mil. Therefore, Anbio Biotechnology's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 18.00%.
The historical rank and industry rank for Anbio Biotechnology's Return-on-Tangible-Asset or its related term are showing as below:
NNNN'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 13.66 Med: 26.05 Max: 106.08
Current: 25
During the past 5 years, Anbio Biotechnology's highest Return-on-Tangible-Asset was 106.08%. The lowest was 13.66%. And the median was 26.05%.
NNNN's Return-on-Tangible-Asset is ranked better than 97.31% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.76
vs NNNN: 25.00
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Anbio Biotechnology Return-on-Tangible-Asset Related Terms
Anbio Biotechnology Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNNN vs ANGO, OSUR, UTMD: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 18.00% mean?
Anbio Biotechnology (NNNN) has a Return-on-Tangible-Asset of 18.00% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Anbio Biotechnology and its competitors. This is 31% below median its historical median of 26.05. Over the past decade, Anbio Biotechnology's Return-on-Tangible-Asset has ranged from 13.66 to 106.08. According to the industry distribution chart, Anbio Biotechnology ranks #23 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 2.7%.
Is Anbio Biotechnology's Return-on-Tangible-Asset too high?
Anbio Biotechnology's current Return-on-Tangible-Asset of 18.00% is 31% below median its 10-year median of 26.05. Over the past 10 years, this metric has ranged from a low of 13.66 to a high of 106.08. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.76. Anbio Biotechnology's value of 18.00% is 2268.4% above this industry median. Based on the distribution chart, Anbio Biotechnology ranks #23 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's Return-on-Tangible-Asset compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #23 out of 855 companies for Return-on-Tangible-Asset. This places Anbio Biotechnology in the top 3% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.76. Anbio Biotechnology's value of 18.00% is 2268.4% above this benchmark. Historically, Anbio Biotechnology's own Return-on-Tangible-Asset has ranged from 13.66 to 106.08 over the past decade. While the company's 10-year median is 26.05 vs. the industry median of 0.76, Anbio Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.76, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current Return-on-Tangible-Asset of 18.00% is 2268.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current Return-on-Tangible-Asset is 18.00%, which is 31% below median its own 10-year median of 26.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current Return-on-Tangible-Asset of 18.00%. The current Return-on-Tangible-Asset is 18.00%, which is 31% below median its 10-year median of 26.05 and 2268.4% above the Medical Devices & Instruments industry median of 0.76. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current Return-on-Tangible-Asset is 18.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
